Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for platelet engraftment after allogeneic hematopoietic stem cell transplantation
ChiCTR2600134562Phase 4Completed
- Sponsor
- Zhejiang Provincial Hospital of Traditional Chinese Medicine
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in Hematopathy and Thrombocytopenia, sponsored by Zhejiang Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Platelet engraftment rate by day +28. Started May 2024; status: completed.
02
Drugs
romiplostim
03
Conditions
HematopathyThrombocytopenia
Beyond the preview
Go deeper on ChiCTR2600134562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134562.